Cancer Discovery

OCT 19, 2026 · JOURNAL ARTICLE

H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer

Cancer Discovery

Non-genetic intratumor heterogeneity underlies therapeutic failure in cancer, yet how resistant tumor states are encoded in patients remains unclear. In this study, we show that ch

OCT 7, 2026 · JOURNAL ARTICLE

Nobel Prize Spotlights Optogenetics’ Reach into Cancer

Cancer Discovery

Abstract Optogenetics, the Nobel-winning technology developed for neuroscience, is giving cancer researchers an unusually precise way to probe how tumors respond to signals from th

SEP 29, 2026 · JOURNAL ARTICLE

Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery

Cancer Discovery

Neoantigen-targeted T-cell therapies require invasive tumor biopsies to identify neoantigens and reactive T cells, limiting their applicability and potentially underestimating tumo

SEP 29, 2026 · JOURNAL ARTICLE

Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

Cancer Discovery

Abstract Effective MAPK-targeted therapies require greater pathway inhibition in tumors than in normal tissues. Although pan-RAF inhibitors have demonstrated activity in RAS-mutant

SEP 18, 2026 · JOURNAL ARTICLE

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts

Cancer Discovery

B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical

SEP 18, 2026 · JOURNAL ARTICLE

Phase III Trials Test First-Line Options in Advanced NSCLC

Cancer Discovery

Abstract: Presented at the 2026 World Conference on Lung Cancer, two phase III trials—PAPILLON and REZILIENT3—established amivantamab and zipalertinib combination therapies as effe

SEP 17, 2026 · JOURNAL ARTICLE

Anti–B7-H3 ADCs Take Center Stage against SCLC at WCLC

Cancer Discovery

Abstract: Separate phase III trials of the anti–B7-H3 antibody–drug conjugates tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-fr

SEP 9, 2026 · JOURNAL ARTICLE

Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities

Cancer Discovery

A narrative review synthesizing mechanistic evidence and therapeutic concepts without reporting new experimental data, clinical trials, or original empirical results.